The rapid adoption of GLP-1 drugs like Ozempic and Wegovy for weight loss is reshaping the aesthetic surgery market in Spain, with nearly 90% of plastic surgeons reporting a rise in patients seeking corrective procedures for loose skin and facial volume loss. This trend signals a growing demand for body contouring and facial rejuvenation among middle-aged women, creating new opportunities for device and consumable suppliers targeting post-weight-loss aesthetics.
Market signal
A survey by the Spanish Association of Aesthetic Plastic Surgery (AECEP) among about 150 specialists found that 90% have seen an increase in patients who lost weight using semaglutide-based medications. The phenomenon has intensified over the past year, mirroring trends in the United States and other European countries. The typical patient profile is women aged 45 to 60, whose skin elasticity is naturally lower, making them more prone to sagging after rapid fat loss.
Most requested procedures
Abdominoplasty (tummy tuck) is the most sought-after surgery, cited by nearly 9 out of 10 surgeons. Other popular body procedures include arm lift (46%), thigh lift (35%), and full body lift (28%). On the face, the top interventions are facelift (60%), hyaluronic acid fillers (44%), blepharoplasty (43%), and collagen biostimulators (30%). Many patients also seek relief from functional issues like chafing and skin irritation caused by excess skin.
What buyers should watch
Distributors and clinic buyers should note the rising demand for body contouring devices, surgical instruments for abdominoplasty and lifts, and facial injectables such as hyaluronic acid fillers and collagen stimulators. The trend also highlights a need for post-weight-loss skincare products that address skin laxity and volume loss. Suppliers of consumables for these procedures—like sutures, drains, and compression garments—may see increased orders from Spanish clinics.
Regulatory and channel signals
Ozempic and Wegovy are regulated by the European Medicines Agency and the Spanish Agency for Medicines and Health Products for specific indications, including type 2 diabetes and obesity with risk factors. The aesthetic market is adapting to a new patient base that requires multidisciplinary follow-up, combining pharmacological treatment with diet, exercise, and medical supervision. This creates opportunities for clinics to bundle aesthetic procedures with weight management programs.
Sourcing context
Spain is following a pattern first observed in the United States, where the term "Ozempic Face" has become common. Similar increases in body and face tightening consultations have been reported in the UK, France, and Germany. For overseas suppliers, this means a consistent European demand for devices and products that address skin laxity and volume loss, particularly among women aged 45-60. The AECEP survey indicates that 83% of post-weight-loss aesthetic patients are women.
Source: Read the original report | Published: June 08, 2026